Drug Trial Radar · NCT01384435
A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Last checked: Nov 19, 2026Latest source record: Dec 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Planned (sponsor's estimate)
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of KPS-0373 compared to placebo in patients with Spinocerebellar Degeneration (SCD).
Conditions
- SCD
Interventions
KPS-0373Drug
KPS-0373Drug
KPS-0373Drug
KPS-0373Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Scale for the assessment and rating of ataxia (SARA)Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Japan
Tokyo and Other Japanese City, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.